Overview

This trial is active, not recruiting.

Condition alzheimer disease
Treatment far infrared radiation (5μm to 20μm wavelength)
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date February 2008
End date March 2009
Trial size 4 participants
Trial identifier NCT00599469, GAAD-AD-CTP1

Summary

Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Other)
Far Infrared Radiation
far infrared radiation (5μm to 20μm wavelength)
Far Infrared radiation for 30 to 40 minutes per treatment session.

Primary Outcomes

Measure
Management and Cure of Alzheimer's Disease
time frame: 1 year

Secondary Outcomes

Measure
Management and Cure of Dementia
time frame: 1 year

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - People with Alzheimer's disease Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.
Principal investigator Ken Nedd, M.D.
Description Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal. Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..